This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, T. Articles by Yang, A.-G. Search for Related Content PubMed PubMed Citation Articles by Wang, T. Articles by Yang, A.-G.

Recombinant Immunoproapoptotic Proteins with Furin Site Can Translocate and Kill HER2-Positive Cancer Cells

¹ State Key Laboratory of Cancer Biology, Departments of Biochemistry and Molecular Biology and ² Immunology and ³ Biotechnology Center, Fourth Military Medical University, Xi'an, China and ⁴ Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas

Requests for reprints: An-Gang Yang, Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China. Phone: 86-29-84774528; Fax: 86-29-83253816; E-mail: agyang{at}fmmu.edu.cn.

We previously reported the selective killing of HER2-positive tumor cells by a class of immunoproapoptotic proteins containing single-chain antibody, translocation domain of Pseudomonas exotoxin A (domain II; PEA II), and constitutively active human apoptotic molecules. In this study, a novel class of antitumor immunoproapoptotic proteins was explored to mediate tumor-specific apoptosis both in vitro and in vivo. Three furin cleavage sequences, including a synthetic polyarginine tract, and two furin cleavable sequences from PEA and diphtheria toxin were respectively used to replace PEA II in the previously constructed immunoproapoptotic protein. When produced and secreted by the genetically modified Jurkat cells, the novel targeted proapoptotic proteins selectively bound to HER2, which is often overexpressed on tumor cell surface. Followed by receptor-mediated endocytosis and furin cleavage in the endosome, the recombinant proteins could translocate into the cytosol, leading to irreversible cell death. Moreover, delivery of these proteins by either i.m. plasmid injection or i.v. injection of plasmid-expressing Jurkat cells led to tumor regression and prolonged animal survival in a nude mouse xenograft tumor model, indicating in vivo antitumor activity of the recombinant proteins. We conclude that the new class of immunoproapoptotic proteins show comparable activity with PEA II–containing counterpart and provide an attractive therapeutic alternative as they contain much less exogenous fragments. [Cancer Res 2007;67(24):11830–39]

This article has been cited by other articles:

				E. O. Serebrovskaya, E. F. Edelweiss, O. A. Stremovskiy, K. A. Lukyanov, D. M. Chudakov, and S. M. Deyev Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein PNAS, June 9, 2009; 106(23): 9221 - 9225. [Abstract] [Full Text] [PDF]